Skip to content

Feasibility and effectiveness of a self-help smartphone app to reduce anxiety: A randomized controlled trial

Feasibility and effectiveness of a self-help smartphone app to reduce anxiety: A randomized controlled trial - COGITO-anxiety

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00035917
Enrollment
238
Registered
2025-01-15
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F40 F41

Interventions

Group 1: The first arm of the study comprises the intervention group, which consists of participants with self-reported anxiety (see: Disease/health problem under investigation). The intervention grou

Sponsors

Universitätsklinikum Hamburg-Eppendorf
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: a) presence of anxiety symptoms, b) age of 18-75 years, c) informed consent to participate in the study, d) sufficient command of German, e) willingness to participate in three anonymous online surveys, f) willingness to use the app independently

Exclusion criteria

Exclusion criteria: a) bipolar or psychotic disorder, b) acute suicidal tendencies

Design outcomes

Primary

MeasureTime frame
The Generalized Anxiety Disorder Scale 7 (GAD-7) is used as the primary outcome to measure changes in anxiety symptoms at the beginning of the study (baseline survey), after six weeks of using the app (post-intervention survey) and after a further three months (follow-up survey).

Secondary

MeasureTime frame
- reduction of depressive symptoms, measured with the Patient Health Questionnaire (PHQ-9) - improvement in quality of life, measured with the global item of the World Health Organization Quality of Life Scale - Brief Version (WHOQOL-Bref) - improvement in self-esteem, measured with the Rosenberg Self-Esteem Scale (RSE) - subjective satisfaction with the app, measured using the Questionnaire for Measuring Patient Satisfaction (ZUF-8) The measurements are assessed at the beginning of the study (baseline survey), after six weeks of using the app (post-intervention survey) and after a further three months (follow-up survey).

Countries

Austria, Germany, Switzerland

Contacts

Public ContactSteffen Moritz

Universitätsklinikum Hamburg-Eppendorf

moritz@uke.de+49 40 7410 56565

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026